First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.

First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.

To report the nonrandomized first-in-human phase I trial of PRS-050, a novel, rationally engineered Anticalin based on human tear lipocalin that targets and antagonizes vascular endothelial growth factor A (VEGF-A).Patients with advanced solid tumors received PRS-050 at 0.1 mg/kg to 10 mg/kg by IV i...

Full description

Bibliographic Details
Main Authors: Klaus Mross, Heike Richly, Richard Fischer, Dirk Scharr, Martin Büchert, Angelika Stern, Hendrik Gille, Laurent P Audoly, Max E Scheulen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3862718?pdf=render

Internet

http://europepmc.org/articles/PMC3862718?pdf=render

Similar Items